Brokerages expect Histogenics Corporation (NASDAQ:HSGX) to announce ($0.31) earnings per share for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Histogenics Corporation’s earnings. Histogenics Corporation posted earnings of ($0.61) per share in the same quarter last year, which suggests a positive year-over-year growth rate of 49.2%. The business is scheduled to issue its next earnings results before the market opens on Thursday, August 10th.
According to Zacks, analysts expect that Histogenics Corporation will report full-year earnings of ($1.65) per share for the current fiscal year, with EPS estimates ranging from ($1.99) to ($1.31). For the next fiscal year, analysts forecast that the company will report earnings of ($1.21) per share, with EPS estimates ranging from ($1.63) to ($0.79). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that follow Histogenics Corporation.
Histogenics Corporation (NASDAQ:HSGX) last issued its earnings results on Thursday, May 11th. The biotechnology company reported ($0.27) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.34) by $0.07. During the same period last year, the company posted ($0.60) earnings per share.
HSGX has been the subject of several research reports. Zacks Investment Research upgraded shares of Histogenics Corporation from a “hold” rating to a “buy” rating and set a $2.00 target price for the company in a research report on Tuesday, May 16th. HC Wainwright set a $4.00 price target on shares of Histogenics Corporation and gave the company a “buy” rating in a research report on Saturday, May 13th. Canaccord Genuity restated a “buy” rating on shares of Histogenics Corporation in a research report on Thursday, May 11th. Finally, ValuEngine upgraded shares of Histogenics Corporation from a “strong sell” rating to a “sell” rating in a research report on Friday, June 23rd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average target price of $5.10.
A number of hedge funds have recently bought and sold shares of HSGX. Sabby Management LLC raised its stake in Histogenics Corporation by 15.9% in the first quarter. Sabby Management LLC now owns 1,095,422 shares of the biotechnology company’s stock valued at $1,895,000 after buying an additional 150,531 shares during the last quarter. Renaissance Technologies LLC raised its stake in Histogenics Corporation by 51.1% in the fourth quarter. Renaissance Technologies LLC now owns 99,000 shares of the biotechnology company’s stock valued at $165,000 after buying an additional 33,500 shares during the last quarter. Finally, Carl Domino Inc raised its stake in Histogenics Corporation by 2.8% in the first quarter. Carl Domino Inc now owns 89,400 shares of the biotechnology company’s stock valued at $155,000 after buying an additional 2,400 shares during the last quarter. Institutional investors and hedge funds own 50.09% of the company’s stock.
Shares of Histogenics Corporation (HSGX) traded up 0.5430% during midday trading on Friday, hitting $1.8701. The company’s stock had a trading volume of 23,366 shares. The stock’s 50 day moving average is $1.80 and its 200-day moving average is $1.72. Histogenics Corporation has a 52-week low of $1.45 and a 52-week high of $4.47. The firm’s market cap is $41.45 million.
About Histogenics Corporation
Histogenics Corporation is a regenerative medicine company. The Company is focused on developing and commercializing products in the musculoskeletal segment of the marketplace. The Company’s product candidate, NeoCart utilizes various aspects of regenerative medicine platform to develop a tissue implant intended to treat tissue injury in the field of orthopedics, specifically cartilage damage in the knee.
Get a free copy of the Zacks research report on Histogenics Corporation (HSGX)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Histogenics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Histogenics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
